CARE-MS: comparison of alemtuzumab with Rebiff efficacy in multiple sclerosis, NEDA: no evidence of disease activity, EDSS: expanded disability status score, CDI: confirmed disability improvement, SIP-1: sphingosine 1 phosphate receptors, IFN-B: interferon-beta, EF-2: elongation factor-2, IL-17: interleukin-17, IFN-gamma: interferon-gamma, TNF-a: tumor necrosis factor-a, TH-1: T-helper 1. This evidence concerns the gene TNF and multiple sclerosis.